The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case-control study.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
09 2023
Historique:
medline: 15 9 2023
pubmed: 12 7 2023
entrez: 12 7 2023
Statut: ppublish

Résumé

The two main phenotypes of multiple sclerosis (MS), primary progressive (PPMS) and relapsing Onset (ROMS), show clinical and demographic differences suggesting possible differential risk mechanisms. Understanding the heritable features of these phenotypes could provide aetiological insight. To evaluate the magnitude of familial components in PPMS and ROMS and to estimate the heritability of disease phenotypes. We used data from 25,186 MS patients of Nordic ancestry from the Swedish MS Registry between 1987 and 2019 with known disease phenotype (1593 PPMS and 16,718 ROMS) and 251,881 matched population-based controls and 3,364,646 relatives of cases and controls. Heritability was calculated using threshold-liability models. For familial odds ratios (ORs), logistic regression with robust sandwich estimator was utilized. The OR of MS diagnosis in those with a first-degree family member with ROMS was 7.00 and 8.06 in those with PPMS. The corresponding ORs for having a second-degree family member with ROMS was 2.16 and 2.18 in PPMS. The additive genetic effect in ROMS was 0.54 and 0.22 in PPMS. Risk of MS increases by several folds in those with a relative with MS. The likelihood of developing either disease phenotype appears independent of genetic predisposition.

Sections du résumé

BACKGROUND
The two main phenotypes of multiple sclerosis (MS), primary progressive (PPMS) and relapsing Onset (ROMS), show clinical and demographic differences suggesting possible differential risk mechanisms. Understanding the heritable features of these phenotypes could provide aetiological insight.
OBJECTIVES
To evaluate the magnitude of familial components in PPMS and ROMS and to estimate the heritability of disease phenotypes.
METHODS
We used data from 25,186 MS patients of Nordic ancestry from the Swedish MS Registry between 1987 and 2019 with known disease phenotype (1593 PPMS and 16,718 ROMS) and 251,881 matched population-based controls and 3,364,646 relatives of cases and controls. Heritability was calculated using threshold-liability models. For familial odds ratios (ORs), logistic regression with robust sandwich estimator was utilized.
RESULTS
The OR of MS diagnosis in those with a first-degree family member with ROMS was 7.00 and 8.06 in those with PPMS. The corresponding ORs for having a second-degree family member with ROMS was 2.16 and 2.18 in PPMS. The additive genetic effect in ROMS was 0.54 and 0.22 in PPMS.
CONCLUSION
Risk of MS increases by several folds in those with a relative with MS. The likelihood of developing either disease phenotype appears independent of genetic predisposition.

Identifiants

pubmed: 37435869
doi: 10.1177/13524585231185258
pmc: PMC10503245
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1209-1215

Références

Mult Scler. 2017 Nov;23(13):1782-1785
pubmed: 28090800
Nat Rev Neurol. 2017 Jan;13(1):25-36
pubmed: 27934854
Methods Mol Biol. 2011;675:215-20
pubmed: 20949391
Epidemiology. 2019 Mar;30(2):230-233
pubmed: 30721167
Clin Neuroradiol. 2022 Sep;32(3):625-641
pubmed: 35258820
Brain. 2014 Mar;137(Pt 3):770-8
pubmed: 24441172
Mult Scler. 2015 Oct;21(11):1404-13
pubmed: 25583848
Stat Med. 2017 May 10;36(10):1599-1618
pubmed: 28114748
J Neurol. 2019 Feb;266(2):481-486
pubmed: 30578428
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Am J Epidemiol. 2005 Oct 15;162(8):774-8
pubmed: 16120694
Mult Scler. 2022 Mar;28(3):359-368
pubmed: 34100315

Auteurs

Graysen Steele Boles (GS)

Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.

Jan Hillert (J)

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.

Ryan Ramanujam (R)

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.

Helga Westerlind (H)

Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.

Tomas Olsson (T)

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Centre for Molecular Medicine (CMM), Department of Clinical Neurosciences, Karolinska Institute, Stockholm, Sweden.

Ingrid Kockum (I)

Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Centre for Molecular Medicine (CMM), Department of Clinical Neurosciences, Karolinska Institute, Stockholm, Sweden.

Ali Manouchehrinia (A)

The Karolinska Neuroimmunology & Multiple Sclerosis Centre, Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden.
Centre for Molecular Medicine (CMM), Department of Clinical Neurosciences, Karolinska Institute, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH